Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA to Review Zanidatamab BLA for HER2+ Metastatic Biliary Tract Cancer

April 2nd 2024

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

Dr Pedersen on the Evolution of Immunotherapy in HCC

April 1st 2024

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.

Dr Dotan on Treating Geriatric Patients With Gastroesophageal Cancer

March 29th 2024

Efrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

Leveraging Immunotherapy in GI Malignancies: Research, Including Organoids and Ablation

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.

Leveraging Immunotherapy in GI Malignancies: A Shift in Drug Discovery

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.

Leveraging Immunotherapy in GI Malignancies: Assays for Early Detection and Prevention

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts explain the challenges faced with preventing or detecting these cancers early and the understanding needed to develop effective early detection methods and move the needle forward.

Leveraging Immunotherapy in GI Malignancies: Is Multicancer Early Detection Becoming a Reality?

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.

Dr Sahin on the Utility of the Northstar Response Assay in GI Cancer

March 28th 2024

Ilyas Sahin, MD, discusses the potential utility of Northstar Response assay in patients with advanced gastrointestinal cancer.

Navigating First-Line Treatment Options in Advanced, Unresectable HCC

March 26th 2024

Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.

Japan’s MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer

March 26th 2024

The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

FDA Grants Fast Track Status to PT886 for Metastatic Claudin 18.2+ Pancreatic Adenocarcinoma

March 22nd 2024

PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.

FDA Green Lights Fluorouracil Safety Label Update Regarding Use in Patients With DPD Deficiency

March 21st 2024

The FDA has approved safety label changes for fluorouracil products to include information regarding the agent’s use in patients with DPD.

First-Line Nivolumab/Ipilimumab Combo Meets OS End Point in Advanced HCC

March 20th 2024

Improved overall survival was achieved with nivolumab plus ipilimumab vs standard-of-care TKIs in patients with advanced hepatocellular carcinoma.

Post-Hoc Analysis Shows Dose-Escalated Radiation is Safe and Efficacious in Intrahepatic Cholangiocarcinoma

March 15th 2024

A post-hoc analysis showed dose escalation of radiation therapy was safe and elicited similar efficacy in intrahepatic cholangiocarcinoma.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

March 15th 2024

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy

March 14th 2024

The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.

Dr Pedersen on the Evolving Use of Cytoreductive Surgery for Peritoneal Carcinomatosis

March 13th 2024

Katrina S. Pedersen, MD, MS, discusses the evolving use of cytoreductive surgery for patients with peritoneal carcinomatosis.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

European Medicines Agency Grants Orphan Drug Designation to Tinengotinib for Biliary Tract Cancer

March 11th 2024

Tinengotinib has been awarded orphan drug designation from the European Medicines Agency for use in select patients with biliary tract cancer.